The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

The following is a summary of “Assessing disease control in patients with atopic dermatitis by using the atopic dermatitis ...

Adbry was approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of adults with moderate-to-severe ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Eczema affects millions of Americans, and any number of environmental and health factors can trigger flare-ups. What should ...

Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults ...

Atopic dermatitis can have a significant impact on quality of life in adolescents, so new efficient treatments are needed to ...

The substantial correlation between prurigo nodularis (PN) and atopic dermatitis (AD) has been highlighted by a recent ...

Eosinophilic esophagitis (EoE), a disorder of the esophagus, is increasingly recognized as a major cause of swallowing ...